Mead Enfamil Sales Buoy Bristol-Myers Nutritionals In Q2
This article was originally published in The Tan Sheet
Executive Summary
Increased spending on consumer ads and promos for Enfamil infant formula helped the brand post worldwide sales gains of roughly 8% to $172 mil. for the second quarter, Bristol-Myers Squibb's Mead Johnson division said July 25.
You may also be interested in...
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said
McNeil Supplements Nutritionals Portfolio With Viactiv
Johnson & Johnson's Viactiv acquisition adds a popular calcium supplement to its nascent McNeil Nutritionals division of niche products.
FDA funding
House passes agriculture spending bill by 414-16 vote July 11; Senate Appropriations Committee will take up legislation July 17. Bill includes $4.14 bil. for Special Supplemental Nutrition Program for Women, Infants & Children (WIC) and an amendment to provide an additional $2.5 mil. for FDA's Office of Generic Drugs. Agency and center funding remains largely unchanged since June debate (1"The Tan Sheet" June 18, In Brief)